| Original language | English (US) |
|---|---|
| Pages (from-to) | 787-790 |
| Number of pages | 4 |
| Journal | The Lancet |
| Volume | 392 |
| Issue number | 10149 |
| DOIs |
|
| State | Published - Sep 1 2018 |
Bibliographical note
Funding Information:CLan reports receipt of products for evaluation in clinical trials from various pharmaceutical companies, including Merck, GlaxoSmithKline, Johnson & Johnson, and Gilead; the clinical trials in which these products are used are not funded by the pharmaceutical companies. PP reports grants from the European Innovative Medicines Initiative outside of the submitted work. DW-J is an investigator on several clinical trials of prophylactic Ebola vaccines. HL reports grants from GlaxoSmithKline and other support from Merck in relation to the submitted work. RT reports grants from the European Innovative Medicines Initiative (Janssen) in relation to the submitted work. AA reports grants from the Alliance for International Medical Action in relation to the submitted work. DI reports non-financial support from Janssen and Merck in relation to the submitted work. GC reports grants from Inserm, and other support from Janssen and Merck in relation to the submitted work. BG reports grants from the Innovative Medicines Initiative (to the London School of Hygiene & Tropical Medicine) in relation to the submitted work. JN reports grants from National Institutes of Health in relation to the submitted work. YY reports receipt of consultancy honoraria from AbbVie, Bristol-Myers Squibb, Gilead, MSD, Pfizer, Johnson & Johnson, and ViiV Healthcare outside the topic of this work, prior to November, 2016. All other authors declare no competing interests.
